�Թ���

The National Academy of Inventors (NAI) today announced that CU Boulder researchers and spinout founders Mark Rentschler, Greg Rieker and Tin Tin Su have been designated as NAI Senior Members in recognition of their impact on society through extraordinary innovation.

Arpeggio Bio is a therapeutics company that is developing cancer treatments. They share how they used their own technology to do drug discovery, and sold it as “consulting” to build credibility with investors and trust with a few initial clients.

In a statement, the Boulder company said the additional funds were part of a second close of its Series A round this year, bringing its total fundraising haul to the year to $214 million in both cash and non-cash funding. SomaLogic is developing blood-testing platforms to measure for thousands of proteins in a patient’s blood or urine sample that may signal current illnesses or risks for developing a future health condition.

CBSA celebrated companies and organizations driving new health innovations to save and change lives around the world during their 2020 virtual Annual Awards Celebration.

Their lead product, Onyx™ is based on tech exclusively licensed from CU Boulder.

Mechanical Engineering Professor Franck Vernerey, Assistant Mechanical Engineering Professor Carson Bruns and ATLAS Institute received $477,000 from the National Science Foundation to begin this three-year project in January 2021. Their research may one day enable soft machines to fully integrate with our bodies to deliver drugs, target tumors, or repair aging or dysfunctional tissue.

Led by professors Jianliang Xiao and Wei Zhang, researchers are developing a wearable electronic device that’s “really wearable”—a stretchy and fully-recyclable circuit board that’s inspired by, and sticks onto, human skin.

The company was co-founded by CTO Dana Anderson, who is also a fellow of JILA and professor in the department of physics and electrical & computer engineering.

MyoKardia was co-founded by Leslie Leinwand, Distinguished Professor of Molecular, Cellular, and developmental Biology at CU Boulder's BioFrontiers Institute, in 2012. Leinwand and her research lab continue to collaborate with the company, currently on finding new treatments for rare genetic diseases.

Researchers at CU Boulder and CU Anschutz have developed a new way to diagnose diseases of the blood like sickle cell disease with sensitivity and precision and in only one minute.